HIV and HIV counselling

Original article by Tom Leach | Last updated on 25/5/2014
Printer-friendly version

Epidemiology

  • 40 million cases worldwide
  • Incidence – 5m/year
  • Deaths – 3m/year
  • Prevalence of AIDS - >3million
  • Most of these are women and children in Africa
  • Types of virus
    • HIV-1 – the most prevalent type in Europe
    • HIV-2 causes a similar disease, but has a longer latency period
  • UK incidence – 7500/year
  • More common in heterosexual individuals than homosexual individuals since 1999.
 

Transmission

Sexual

75% sexual intercourse
5-7% oral sex
Evidence suggests that circumcision reduces the risk of infection by 60% - however there is some public belief that it provides immunity – it does not!
Risks (per sexual encounter):

  • Anal sex – receiving partner – between 0.1 – 3%
  • Anal sex – active partner - <0.1%
  • Vaginal sex – female – 1 in 100,000
  • Vaginal sex – male – 1 in 200,000
  • Oral sex – less than 1 in 200,000
  • Child birth – 15%
  • Child birth + breast feeding – 25%

Blood products
IV drug use
Vertical transmission

 

Pathology

HIV is an RNA retrovirus. The virus is incorporated into a host cell, whereby, the viral enzyme transcriptase will begin transcription of the RNA to DNA. Then, the viral enzyme integrase will integrate the DNA into the host’s.

  • The host cell will then produce viral polypeptides, which are cleaved into functional viral parts by the viral enzyme protease.
  • Finally, complete virions are released by the host cell via budding

Infection of cells - These new virion can now infect new cells. They are capable of entering any cell that expresses the CD4 receptor. The virus will bind to CD4 receptors with the gp120 glycoprotein. Susceptible cells include:

  • CD4+ T cells
  • Macrophages
  • Monocytes
  • Neurons

CD4+ T cells will migrate to lymphoid tissue, and release millions of virons, ready to infect new cells.
As the infection progresses, destruction of CD4+ cells leads to reduced efficacy of the host immune system.  

 

Clinical features

HIV infection can be divided into stages:

Seroconversion – typically occurs 2-6 weeks after exposure. Is often asymptomatic, but in some individuals there may be a period of fever, malaise, myalgia, pharygnitis and maculopapular rash.
Asymptomatic infection – this can last for years

  • 30% of patients will have a persistent generalized lymphadenopathy (PGL) – where there are lymph nodes 1cm in diameter at >2 extra-inguinal sites. This may last >3 months.

AIDS related complex (ARC) – this is a set of prodromal symptoms that precedes the onset of AIDS. It can include:

  • Opportunistic infection (e.g. candidal infection, herpes etc)
  • Night sweats
  • High temp
  • Diarrhoea

AIDS

  • There is marked immunodeficiency
  • Typically defined as a CD4 count <200 x 106 / L
 

Diagnosis

P24 antigen – present in the blood in the first 3 months of infection. Usually levels drop by the time IgG and IgM are produced (3 months). Levels rise again as immunodeficiency develops.
HIV RNA – can also be detected using PCR techniques during the early stages of the infection

  • Used to monitor progress and effectiveness of treatment (See below)

IgG and IgM – levels detectable after 3 months. Fall as immunodeficiency develops (try looking for P24).
OraQuick – is a method of detecting HIV antibodies in saliva. Fast and easy, but high false positives.
HIV and TBoften co-exist, and can be a real problem.

  • 30-50% of those with AIDS also have TB
  • Mantoux test can be negative even in positive patients
  • TB presentation is often atypical
  • AFB (Acid-fast bacilli) Smearmay be negative, or have very few cells. Important to culture for sensitivities.
  • All HIV positive patients should be regularly monitored for TB. Some recommend the use of isoniazid as prophylaxis in HIV positive patients.
 

Monitoring

The following should be measured every 3 months:

HIV RNA levels – strongly predict the progression to AIDS, regardless of the CD4 count!

  • Patients can be ‘staged’ according to HIV RNA levels, e.g.:
  • Those in the lowest quartile have an 8% of progressing to AIDS in 5 years, compared to 62% of those in the highest quartile.

CD4 count

  • In the developing world, this test may be too expsenive. A total lymphocytes count may be adequate
  • Total lymphocytes = 1400, then CD4 roughly =200
  • This is accurate enough for predicting HIV progression

Viral load

 

Management

All newly diagnosed HIV positive patients should be tested for:

 

HAART – highly active anti-retroviral therapy

  • In the developed world, this is the mainstay of treatment. There is not one specific recommended regimen – essentially all regimens are experimental combinations of anti-retroviral drugs
  • It aims to reduce the rate of viral replication below detectable levels. This does not mean that replication is not occurring!
  • HAART should be part of a holistic care approach.
  • It is a combination of two Nuceloside analogue reverse transcriptase inhibitors (NRTI’s), PLUS
    • Either; a Protease Inhibitor (PI),
    • Or; a non-nucleoside reverse transcriptase inhibitor (NNRTI)

 

Principles of therapy

always use >3 drugs (don’t do double therapy)
Start treatment as early as possible – i.e. before CD4 count <200
When to start treatment?

  • Any patient with AIDS
  • Any patient with CD4 <200
    • Will probably be revised upwards soon (<275-300)

Any patient with CD4 200-350 with high viral load
Any patient with CD4 200-350, but CD4 falling fast

  • Advise the patient that regimens are complex, and require strict adherence
  • Monitor Viral load and CD4 count regularly.
  • Ideally, viral load will be undetectable after 4 months of HAART
  • If viral load is apparently erratic, consider poor adherence
  • If firal load remains high despite treatment, change the regimen
 

NRTI’s – e.g. Zidovudine, Didanosine, Lamivudine, Emtricitabine, Tenofovir, Abacavir

  • Side effect are not particularly pleasant, and include:
  • Anaemia, leucopaenia, GI disturbance, rashes, myalgia, neuropathies, pancreatitis.
  • CI’s: LFT disturbance, Hepatomegaly, lactic acidosis, breast feeding, anaemia. Monitor for liver problems and amylase.
 

Protease Inhibitors – e.g. Indinavir, Ritonavir, Saquinavir, Lopinavir

  • Slow the viral spread, prolong the asymptomatic stage of the disease
  • Metabolized y cytochrome P450 system – so can cause drug interactions
  • Can cause metabolic syndrome (insulin resistance, hyperglycaemia, dyslipidaemia)
  • Side effects: Taste disturbance, rash, pruritus (itch), hyperpigmentation, alopecia, parasthesia, myalgia, headache, dizziness, pancreatitis, anaemia, abnormal LFTs.
 

NNRTI’s e.g. Nevirapine, Efavirenz

 

Prevention

PEP – post-exposure prophylaxis – anti HIV drugs can be taken as prophylaxis, if taken within 72 hours of exposure to HIV. This exposure could be in the form of sexual contact (including oral, vaginal, anal), or blood products contact.
Needlestick injuries
  • Risk of HIV infection is <0.5%
    • Tests for HIV antibodies should be done at 3,6 and 8 months to check for seroconversion
  •  Risk of Hep B infection is about 30%
  • Make it bleed!
    • But do not suck, or put in bleech
  • Get the details of the ‘donor’
  • Report to occupational health ASAP
  • Store blood samples from both parties
  • Check risk
    • Related to the donor CD4 level and viral load
  • Consider prophylaxis
    • Low risk – may not be needed
    • High risk – zidovudine – 250mg / 12h + lamivudine 150mg / 12h + indinavir 800mg / 8hr, all PO
    • Do a pregnancy test before starting on prophylaxis!
    • There have been about 100 cases worldwide, and 5 in the UK, of a healthcare working contracting HIV from a patient
 
Prevention of vertical transmission

15% risk of vertical transmission (higher in Africa)
Methods of prevention of vertical transmission:
All HIV positive mothers should              

  • Take anti-retrovirals – nevirapine is recommended. If on another agent before pregnancy, switch to this once pregnant
  • Consider Caesarian
  • Usually elective caesarean at 38 weeks
  • Vaginal delivery is a RF – if twins, the first twin is at greater risk of vertical transmission
  • Abstain from breast feeding
  • If all the above measures are adhered to, risk of transmission is about 2%.
  • Have tests for genital infection at booking and at 28 weeks
 

Counseling for HIV testing

It is very important to remember that before you perform an HIV test you need to tell the patient about the implications of a positive result. You should:
Determine the level of risk (e.g. unprotected sex, number of partners, sex overseas)
Discuss the benefits of knowing if test is positive:

  • Protect partner
  • Reduce risk of vertical transmission
  • Get treatment

Ask about major concerns e.g.:

  • Telling partner / friends
  • Job
  • Mortgage (if can’t work)
  • Confidentiality
  • You don’t have an obligation to inform the partner as this would break confidentiality. Encourage patient to discuss these issues with partner – offer them to invite partner along to surgery if this would help.
  • However – if the patient refuses to tell their partner, you should consult GUM specialists / MDU / MPS to discuss the cases. In some instances it may be acceptable to break confidentiality to inform those at risk.

Post-term counseling

  • Again discuss effects on family, job, telling partner / friends
  • Emphasize methods to reduce exposure.
  • Long-term counseling – may involve making plans for death, e.g.
    • Making a will
    • Housing
    • Employment
    • Care of children
    • Involvement of GP, palliative care services, and HIV experts